PART 1: Biotech Innovation from Concept to IND to Clinical Development

Date
9:00am - 10:30am
Location
Live Webinar
Speakers:
Yinghong Gao , VP & Associate Business Partner, Viva Biotech , Yinghong Gao, VP of BD & Associate Business Partner at Viva Biotech and its Viva BioInnovator investment division, is an experienced drug R&D scientist turned business development and investment professional. She also serves as a board observer of DTx Pharma. Prior to that, she was an integral team member of target selection, licensing & scientific network of MerckMillipore, responsible for lead evaluation and new product introduction. She has over a decade of drug discovery experience as a medicinal chemist with additional expertise in computer aided drug design, working at biotech companies including Cytel Corporation, Neurocrine Biosciences and Arena Pharmaceuticals with increasing responsibilities. Her successful drug discovery track record is evidenced by over 30 publications and patents, and multiple IND clinical candidates in different therapeutic areas and her indelible contributions to the discovery of ORILISSA®, a GnRH antagonist, which gained FDA approval in 2018. She also has broad CRO experience ranging from early drug discovery to pre-clinical and clinical development. She holds a MSc. Degree from Chinese Academy of Sciences in physical chemistry and a MSc. Degree from Tulane University in organic chemistry. , Samuel V. Alworth, MS, MBA , Chief Executive Officer and Co-Founder, AcuraStem , Samuel V. Alworth, MS, MBA, Chief Executive Officer and Co-Founder of AcuraStem, has nearly 20 years’ experience in the life sciences covering research, drug development and business development. Since co-founding AcuraStem, he has been actively involved in advancing the company's innovative drug candidates for ALS / FTD. With a technical background in machine learning and image recognition, Sam has led the implementation of new informatics pipelines at AcuraStem, incorporating both innovative machine learning and traditional image processing algorithms for the iNeuroRx® platform. Prior to co-founding AcuraStem, Mr. Alworth was VP of Sales & Marketing at DRVision Technologies LLC (Bellevue, WA), where he led the development of an artificial intelligence enabled software for automated microscopy (SVCell, now Aivia). Sam holds several U.S. patents and has contributed to numerous scientific journal publications. ,

Part 1- Viva Biotech & AcuraStem: “Turning Your Idea Into a Fundable Business Plan”

With record breaking biotech investment this year, emerging companies are flourishing and forging new strategic partnerships despite the pandemic. This 3-part webinar series will guide you through the exciting journeys of Biotech Startups From Concept to IND and Clinical Development

Do you have a brilliant idea that you believe may lead to transformative innovation? Are you in the process of getting your new company off the ground? Turning an innovative idea into a fundable business plan can be daunting, especially for first time entrepreneurs. Some of the most frequently asked questions by scientists-turned-entrepreneurs are “what is a business plan?” and “what needs to be included in an investment deck?”

In this informative webinar, you will be hearing from Yinghong Gao of Viva, an early stage life-science investor and incubator, about the key ingredients that investors like Viva are looking for in a business plan and the most relevant building blocks that will help make your investment pitch deck stand out from the pack. Sam Alworth, CEO of AcuraStem, will then share his expertise with the audience from a founder’s perspective, outlining his unique journey, which has led to successful funding to enable AcuraStem’s trailblazing research in neurodegenerative disease drug discovery.

PART 2: Biotech Innovation from Concept to IND to Clinical Development

Date
9:00am - 10:30am
Location
Live Webinar
Speakers:
Matthew D. Durman, Ph.D. , , Dr. Surman is a medicinal chemist with approximately 19 years of experience working on drug discovery projects at Albany Molecular Research, Inc. (AMRI). Dr. Surman received his Ph.D. in synthetic organic chemistry from the University of Notre Dame under the direction of Prof. Marvin J. Miller. He joined the AMRI Medicinal Chemistry department in 2002 and worked on contract research projects spanning a variety of therapeutic areas including oncology (tubulin inhibitors, HSP-90), anti-infectives (FabI, DXP-R) and CNS (D2/5HT2A antagonists). From 2005 to 2011, Dr. Surman was part of the AMRI internal Discovery Research and Development department. His efforts were focused in the area of metabolic disorders, particularly in obesity. He served as the project leader for the AMRI MCH-1 antagonist program from 2008 until returning to the contract Medicinal Chemistry department in late 2011. During that time, the project culminated in the discovery and development of a successful Phase I clinical candidate. Since returning to the Medicinal Chemistry department, he has led the discovery efforts on a number of programs including projects involved in oncology, neurological disease, and pain. Dr. Surman is the co-inventor / co-author on approximately 30 patent applications and publications. ,

Part 2- AMRI: “Early discovery from Concept through IND”

With record breaking biotech investment this year, emerging companies are flourishing and forging new strategic partnerships despite the pandemic. This 3-part webinar will guide you through the exciting journeys of Biotech Startups From Concept to IND and Clinical Development